These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33903096)

  • 21. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
    Baker EH; Patel K; Ball J; Edwards S; Harrison TS; Kaul A; Koh M; Krishna S; Leaver S; Kumar V; Forton DM
    Br J Clin Pharmacol; 2021 Mar; 87(3):1584-1586. PubMed ID: 32656822
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
    Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
    Gangemi S; Tonacci A
    Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covid-19 and leptospirosis: Cytokine storm and the use of steroids.
    Ittyachen AM
    Trop Doct; 2021 Jan; 51(1):128-130. PubMed ID: 33236692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
    Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
    Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
    Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of synthetic glucocorticoids in COVID-19 endothelites.
    Ferrara F; Vitiello A
    Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):1003-1007. PubMed ID: 33443616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series.
    Beltrão BA; Teixeira RC; Porto DB
    J Investig Med High Impact Case Rep; 2021; 9():23247096211037442. PubMed ID: 34334015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019.
    Patel M; Dominguez E; Sacher D; Desai P; Chandar A; Bromberg M; Caricchio R; Criner GJ;
    Chest; 2021 Jan; 159(1):e7-e11. PubMed ID: 32931823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The shortcomings of tocilizumab in COVID-19.
    Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
    Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies.
    Kaminski MA; Sunny S; Balabayova K; Kaur A; Gupta A; Abdallah M; Quale J
    Int J Infect Dis; 2020 Dec; 101():59-64. PubMed ID: 33002613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
    Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
    Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
    [No Abstract]   [Full Text] [Related]  

  • 38. Is IL-6 a key cytokine target for therapy in COVID-19?
    Jones SA; Hunter CA
    Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
    Sarhan NM; Warda AEA; Ibrahim HSG; Schaalan MF; Fathy SM
    Sci Rep; 2023 Apr; 13(1):6456. PubMed ID: 37081046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy.
    Bektaş M; Özdemir G
    Clin Immunol; 2022 Mar; 236():108936. PubMed ID: 35091103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.